The North America Retinal Biologics Market would witness market growth of 4.9% CAGR during the forecast period (2023-2030).
Increases in the prevalence of retinal illnesses such as diabetic retinopathy, age-related macular degeneration (AMD), and retinal vein occlusion have been major drivers of the market growth. Moreover, the Centers for Disease Control and Prevention (CDC) of the US states that the prevalence of AMD generally rises with age, rising from 2% in those aged 40 to 44 to 46.6% in people aged 85 and older.
The American Academy of Ophthalmology (AAO) states that the largest cause of avoidable blindness in the adult working population is diabetic retinopathy, which is still a frequent consequence of diabetes mellitus. Eye problems like retinal vein blockage also requires the use of retinal biologics. The National Library of Medicine reported in May 2023 that central retinal vein blockage is one of the leading causes of unexpected, painless vision loss in individuals.
The demand for retinal biologics is increasing in this region because of the rising rates of macular degeneration, diabetic retinopathy, uveitis, and other eye conditions. According to the Centers for Disease Control and Prevention (CDC), an estimated that 19.8 million people (above 40) had age-related macular degeneration in 2019. Similarly, Health Canada states that every year, about 200,000 new instances of AMD are identified in the nation. The growing prevalence of retinal diseases, the rise in research and development activities, and the expansion of strategic initiatives by major market players are the primary factors driving the growth of the North American market.
Strategic actions performed by the major market participants may further stimulate market expansion. In October 2021, for instance, Novartis gained approval from the U.S. Food and Drug Administration (FDA) for the company's supplemental Biologics License Application (sBLA) for the type-II variant application for Beovu (brolucizumab) 6 mg for the treatment of diabetic macular edema (DME). Hene, the region preset lucrative growth prospects for the market throughout the forecast period.
The US market dominated the North America Retinal Biologics Market by Country in 2022, and would continue to be a dominant market till 2030; thereby, achieving a market value of $7,816.4 million by 2030. The Canada market is experiencing witness a CAGR of 7.3% during (2023 - 2030). Additionally, The Mexico market would exhibit a CAGR of 6.4% during (2023 - 2030).
Based on Indication, the market is segmented into Macular Degeneration, Diabetic Retinopathy and Others. Based on Drug Class, the market is segmented into VEGF-A Antagonist and Others. Based on Distribution Channel, the market is segmented into Hospital Pharmacy, Retail Pharmacy and Online Pharmacy. Based on countries, the market is segmented into U.S., Mexico, Canada, and Rest of North America.
Free Valuable Insights: The Worldwide Retinal Biologics Market is Projected to reach USD 20.7 Billion by 2030, at a CAGR of 5.4%
The market research report covers the analysis of key stake holders of the market. Key companies profiled in the report include Novartis AG, Amgen, Inc., AbbVie, Inc., Bayer AG, Regeneron Pharmaceuticals, Inc., Santen Pharmaceutical Co., Ltd., Bausch Health Companies, Inc., F. Hoffmann-La Roche Ltd., MeiraGTx Holdings plc and Oxurion NV.
Scope of the Study
Market Segments Covered in the Report:
By Indication
- Macular Degeneration
- Diabetic Retinopathy
- Others
By Drug Class
By Distribution Channel
- Hospital Pharmacy
- Retail Pharmacy
- Online Pharmacy
By Country
- US
- Canada
- Mexico
- Rest of North America
Key Market Players
List of Companies Profiled in the Report:
- Novartis AG
- Amgen, Inc.
- AbbVie, Inc.
- Bayer AG
- Regeneron Pharmaceuticals, Inc.
- Santen Pharmaceutical Co., Ltd.
- Bausch Health Companies, Inc.
- F.Hoffmann-La Roche Ltd.
- MeiraGTx Holdings plc
- Oxurion NV
Chapter 1. Market Scope & Methodology
1.1 Market Definition
1.2 Objectives
1.3 Market Scope
1.4 Segmentation
1.4.1 North America Retinal Biologics Market, by Indication
1.4.2 North America Retinal Biologics Market, by Drug Class
1.4.3 North America Retinal Biologics Market, by Distribution Channel
1.4.4 North America Retinal Biologics Market, by Country
1.5 Methodology for the research
Chapter 2. Market at a Glance
2.1 Key Highlights
Chapter 3. Market Overview
3.1 Introduction
3.1.1 Overview
3.1.1.1 Market Composition and Scenario
3.2 Key Factors Impacting the Market
3.2.1 Market Drivers
3.2.2 Market Restraints
3.3 Porter’s Five Forces Analysis
Chapter 4. Strategies deployed in Retinal Biologics Market
Chapter 5. North America Retinal Biologics Market by Indication
5.1 North America Macular Degeneration Market by Country
5.2 North America Diabetic Retinopathy Market by Country
5.3 North America Others Market by Country
Chapter 6. North America Retinal Biologics Market by Drug Class
6.1 North America VEGF-A Antagonist Market by Country
6.2 North America Others Market by Country
Chapter 7. North America Retinal Biologics Market by Distribution Channel
7.1 North America Hospital Pharmacy Market by Country
7.2 North America Retail Pharmacy Market by Country
7.3 North America Online Pharmacy Market by Country
Chapter 8. North America Retinal Biologics Market by Country
8.1 US Retinal Biologics Market
8.1.1 US Retinal Biologics Market by Indication
8.1.2 US Retinal Biologics Market by Drug Class
8.1.3 US Retinal Biologics Market by Distribution Channel
8.2 Canada Retinal Biologics Market
8.2.1 Canada Retinal Biologics Market by Indication
8.2.2 Canada Retinal Biologics Market by Drug Class
8.2.3 Canada Retinal Biologics Market by Distribution Channel
8.3 Mexico Retinal Biologics Market
8.3.1 Mexico Retinal Biologics Market by Indication
8.3.2 Mexico Retinal Biologics Market by Drug Class
8.3.3 Mexico Retinal Biologics Market by Distribution Channel
8.4 Rest of North America Retinal Biologics Market
8.4.1 Rest of North America Retinal Biologics Market by Indication
8.4.2 Rest of North America Retinal Biologics Market by Drug Class
8.4.3 Rest of North America Retinal Biologics Market by Distribution Channel
Chapter 9. Company Profiles
9.1 Novartis AG
9.1.1 Company Overview
9.1.2 Financial Analysis
9.1.3 Segmental and Regional Analysis
9.1.4 Research & Development Expense
9.1.5 Recent strategies and developments:
9.1.5.1 Acquisition and Mergers:
9.1.6 SWOT Analysis
9.2 Amgen, Inc.
9.2.1 Company Overview
9.2.2 Financial Analysis
9.2.3 Regional Analysis
9.2.4 Research & Development Expenses
9.2.5 SWOT Analysis
9.3 AbbVie, Inc.
9.3.1 Company Overview
9.3.2 Financial Analysis
9.3.3 Regional Analysis
9.3.4 Research & Development Expense
9.3.5 Recent strategies and developments:
9.3.5.1 Partnerships, Collaborations, and Agreements:
9.3.5.2 Approvals & Trials:
9.3.6 SWOT Analysis
9.4 Bayer AG
9.4.1 Company Overview
9.4.2 Financial Analysis
9.4.3 Segmental and Regional Analysis
9.4.4 Research & Development Expense
9.4.5 SWOT Analysis
9.5 Regeneron Pharmaceuticals, Inc.
9.5.1 Company Overview
9.5.2 Financial Analysis
9.5.3 Research & Development Expense
9.5.4 SWOT Analysis
9.6 Santen Pharmaceutical Co., Ltd.
9.6.1 Company Overview
9.6.2 Financial Analysis
9.6.3 Regional Analysis
9.6.4 Research & Development Expenses
9.6.5 SWOT Analysis
9.7 Bausch Health Companies, Inc.
9.7.1 Company Overview
9.7.2 Financial Analysis
9.7.3 Segmental and Regional Analysis
9.7.4 Research & Development Expense
9.7.5 Recent strategies and developments:
9.7.5.1 Partnerships, Collaborations, and Agreements:
9.7.5.2 Approvals & Trials:
9.7.5.3 Acquisition and Mergers:
9.7.6 SWOT Analysis
9.8 F. Hoffmann-La Roche Ltd.
9.8.1 Company Overview
9.8.2 Financial Analysis
9.8.3 Segmental and Regional Analysis
9.8.4 Research & Development Expense
9.8.5 Recent strategies and developments:
9.8.5.1 Partnerships, Collaborations, and Agreements:
9.8.5.2 Approvals & Trials:
9.8.6 SWOT Analysis
9.9 MeiraGTx Holdings plc
9.9.1 Company Overview
9.9.2 Financial Analysis
9.9.3 Research & Development Expenses
9.9.4 SWOT Analysis
9.1 Oxurion NV
9.10.1 Company Overview
9.10.2 Financial Analysis
9.10.3 Research & Development Expenses
9.10.4 SWOT Analysis
TABLE 1 North America Retinal Biologics Market, 2019 - 2022, USD Million
TABLE 2 North America Retinal Biologics Market, 2023 - 2030, USD Million
TABLE 3 North America Retinal Biologics Market by Indication, 2019 - 2022, USD Million
TABLE 4 North America Retinal Biologics Market by Indication, 2023 - 2030, USD Million
TABLE 5 North America Macular Degeneration Market by Country, 2019 - 2022, USD Million
TABLE 6 North America Macular Degeneration Market by Country, 2023 - 2030, USD Million
TABLE 7 North America Diabetic Retinopathy Market by Country, 2019 - 2022, USD Million
TABLE 8 North America Diabetic Retinopathy Market by Country, 2023 - 2030, USD Million
TABLE 9 North America Others Market by Country, 2019 - 2022, USD Million
TABLE 10 North America Others Market by Country, 2023 - 2030, USD Million
TABLE 11 North America Retinal Biologics Market by Drug Class, 2019 - 2022, USD Million
TABLE 12 North America Retinal Biologics Market by Drug Class, 2023 - 2030, USD Million
TABLE 13 North America VEGF-A Antagonist Market by Country, 2019 - 2022, USD Million
TABLE 14 North America VEGF-A Antagonist Market by Country, 2023 - 2030, USD Million
TABLE 15 North America Others Market by Country, 2019 - 2022, USD Million
TABLE 16 North America Others Market by Country, 2023 - 2030, USD Million
TABLE 17 North America Retinal Biologics Market by Distribution Channel, 2019 - 2022, USD Million
TABLE 18 North America Retinal Biologics Market by Distribution Channel, 2023 - 2030, USD Million
TABLE 19 North America Hospital Pharmacy Market by Country, 2019 - 2022, USD Million
TABLE 20 North America Hospital Pharmacy Market by Country, 2023 - 2030, USD Million
TABLE 21 North America Retail Pharmacy Market by Country, 2019 - 2022, USD Million
TABLE 22 North America Retail Pharmacy Market by Country, 2023 - 2030, USD Million
TABLE 23 North America Online Pharmacy Market by Country, 2019 - 2022, USD Million
TABLE 24 North America Online Pharmacy Market by Country, 2023 - 2030, USD Million
TABLE 25 North America Retinal Biologics Market by Country, 2019 - 2022, USD Million
TABLE 26 North America Retinal Biologics Market by Country, 2023 - 2030, USD Million
TABLE 27 US Retinal Biologics Market, 2019 - 2022, USD Million
TABLE 28 US Retinal Biologics Market, 2023 - 2030, USD Million
TABLE 29 US Retinal Biologics Market by Indication, 2019 - 2022, USD Million
TABLE 30 US Retinal Biologics Market by Indication, 2023 - 2030, USD Million
TABLE 31 US Retinal Biologics Market by Drug Class, 2019 - 2022, USD Million
TABLE 32 US Retinal Biologics Market by Drug Class, 2023 - 2030, USD Million
TABLE 33 US Retinal Biologics Market by Distribution Channel, 2019 - 2022, USD Million
TABLE 34 US Retinal Biologics Market by Distribution Channel, 2023 - 2030, USD Million
TABLE 35 Canada Retinal Biologics Market, 2019 - 2022, USD Million
TABLE 36 Canada Retinal Biologics Market, 2023 - 2030, USD Million
TABLE 37 Canada Retinal Biologics Market by Indication, 2019 - 2022, USD Million
TABLE 38 Canada Retinal Biologics Market by Indication, 2023 - 2030, USD Million
TABLE 39 Canada Retinal Biologics Market by Drug Class, 2019 - 2022, USD Million
TABLE 40 Canada Retinal Biologics Market by Drug Class, 2023 - 2030, USD Million
TABLE 41 Canada Retinal Biologics Market by Distribution Channel, 2019 - 2022, USD Million
TABLE 42 Canada Retinal Biologics Market by Distribution Channel, 2023 - 2030, USD Million
TABLE 43 Mexico Retinal Biologics Market, 2019 - 2022, USD Million
TABLE 44 Mexico Retinal Biologics Market, 2023 - 2030, USD Million
TABLE 45 Mexico Retinal Biologics Market by Indication, 2019 - 2022, USD Million
TABLE 46 Mexico Retinal Biologics Market by Indication, 2023 - 2030, USD Million
TABLE 47 Mexico Retinal Biologics Market by Drug Class, 2019 - 2022, USD Million
TABLE 48 Mexico Retinal Biologics Market by Drug Class, 2023 - 2030, USD Million
TABLE 49 Mexico Retinal Biologics Market by Distribution Channel, 2019 - 2022, USD Million
TABLE 50 Mexico Retinal Biologics Market by Distribution Channel, 2023 - 2030, USD Million
TABLE 51 Rest of North America Retinal Biologics Market, 2019 - 2022, USD Million
TABLE 52 Rest of North America Retinal Biologics Market, 2023 - 2030, USD Million
TABLE 53 Rest of North America Retinal Biologics Market by Indication, 2019 - 2022, USD Million
TABLE 54 Rest of North America Retinal Biologics Market by Indication, 2023 - 2030, USD Million
TABLE 55 Rest of North America Retinal Biologics Market by Drug Class, 2019 - 2022, USD Million
TABLE 56 Rest of North America Retinal Biologics Market by Drug Class, 2023 - 2030, USD Million
TABLE 57 Rest of North America Retinal Biologics Market by Distribution Channel, 2019 - 2022, USD Million
TABLE 58 Rest of North America Retinal Biologics Market by Distribution Channel, 2023 - 2030, USD Million
TABLE 59 Key Information – Novartis AG
TABLE 60 Key Information – Amgen, Inc.
TABLE 61 Key information – AbbVie, Inc.
TABLE 62 Key Information – Bayer AG
TABLE 63 Key Information – Regeneron Pharmaceuticals, Inc.
TABLE 64 Key Information – Santen Pharmaceutical Co., Ltd.
TABLE 65 key information – Bausch Health Companies, Inc.
TABLE 66 KEY INFORMATION – F. Hoffmann-La Roche Ltd.
TABLE 67 Key Information – MeiraGTx Holdings plc
TABLE 68 Key Information – Oxurion NV
List of Figures
FIG 1 Methodology for the research
FIG 2 North America Retinal Biologics Market, 2019 - 2030, USD Million
FIG 3 Key Factors Impacting Retinal Biologics Market
FIG 4 Porter’s Five Forces Analysis - Retinal Biologics Market
FIG 5 North America Retinal Biologics Market share by Indication, 2022
FIG 6 North America Retinal Biologics Market share by Indication, 2030
FIG 7 North America Retinal Biologics Market by Indication, 2019 - 2030, USD Million
FIG 8 North America Retinal Biologics Market share by Drug Class, 2022
FIG 9 North America Retinal Biologics Market share by Drug Class, 2030
FIG 10 North America Retinal Biologics Market by Drug Class, 2019 - 2030, USD Million
FIG 11 North America Retinal Biologics Market share by Distribution Channel, 2022
FIG 12 North America Retinal Biologics Market share by Distribution Channel, 2030
FIG 13 North America Retinal Biologics Market by Distribution Channel, 2019 - 2030, USD Million
FIG 14 North America Retinal Biologics Market share by Country, 2022
FIG 15 North America Retinal Biologics Market share by Country, 2030
FIG 16 North America Retinal Biologics Market by Country, 2019 - 2030, USD Million
FIG 17 SWOT Analysis: Novartis AG
FIG 18 Swot Analysis: Amgen, Inc.
FIG 19 Swot Analysis: AbbVie, Inc.
FIG 20 Swot Analysis: Bayer AG
FIG 21 Swot Analysis: Regeneron Pharmaceuticals, Inc.
FIG 22 Swot Analysis: Santen Pharmaceutical Co., Ltd.
FIG 23 Recent strategies and developments: Bausch Health Companies, Inc.
FIG 24 Swot Analysis: Bausch Health Companies, Inc.
FIG 25 Swot Analysis: F. Hoffmann-La Roche Ltd.
FIG 26 Swot Analysis: MeiraGTx Holdings plc
FIG 27 Swot Analysis: Oxurion NV